MCLA-158 (Lgr5 x EGFR Biclonics®)

Solid Tumors

Stage (next event)

Next Event

Expected Date

Phase 1

Data readout


Phase 1 trial continues; Update expected by year end

Catalyst Info & Data Links


  • Phase 1 trial continues; Update expected by year end

  • Clinical data from its Phase 1 dose escalation study of MCLA-158 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium (ASCO GI) annual meeting being held virtually from January 15-17, 2021.


Mechanism of Action

MCLA-158 is an antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced Biclonics® for the treatment of solid tumors, including the potential treatment of colorectal cancer, that binds to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal growth factor receptor (EGFR). MCLA-158 is designed to use two different mechanisms of action. The first blocks growth and survival pathways in cancer stem cells. The second involves the recruitment and enhancement of immune effector cells to directly kill cancer stem cells that persist in solid tumors and cause relapse and metastasis.


Prior Data (click to view full image)


Trial Design / Revenue (click to view full image)


Recent Posts

See what the community is saying - click to see full post

Biopharma Daily Stock Updates - 01/21/21

Biopharma Daily Stock Updates - 01/19/21

Biopharma Daily Stock Updates - 01/12/21

Biopharma Daily Stock Updates - 01/07/21

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon